A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended dose of siltuximab monotherapy, in
participants with solid malignant (cancerous) tumors (a mass in a specific area) and to
estimate the clinical benefit of siltuximab monotherapy in participants with ovarian cancer
and with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant tumors.